Nonalcoholic steatohepatitis (NASH) is the advanced subtype of nonalcoholic fatty liver disease (NAFLD) and is becoming a severe global public health problem. PPARα/δ are regarded as potential therapeutic targets for NASH. Herein, researchers report a series of novel triazolone derivatives as PPARα/δ dual agonists.

The pharmacokinetic studies were conducted by Medicilon.

The hERG channel inhibition studies were conducted by Medicilon.

The Ames tests were conducted by Medicilon.

Reference: